ALOMIDE
LOE ApproachingNDAOPHTHALMICSOLUTION/DROPS
Approved
Sep 1993
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ALOMIDE is a small-molecule ophthalmic solution approved in 1993 for multiple myeloma treatment via eye drops. The mechanism of action and specific pharmacologic class are not publicly detailed in available data. This appears to be a niche ophthalmologic formulation for a hematologic malignancy.
$64KPart D
LOE ApproachingDeclining
<1% of multiple myeloma market
Minimal commercial activity with near-term LOE; brand team will be extremely small or consolidating.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
ALOMIDE presents minimal career opportunity; zero linked job positions and <$100K annual spending indicate a skeleton team managing end-of-life operations. Career prospects are limited to defensive/transition roles focused on generic conversion and patient continuity.
Brand ManagerField Sales
Worked on ALOMIDE at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.